6314-39-2

Basic information

• Product Name: 1-benzothiophen-2-yl[4-(dimethylamino)phenyl]methanol
• CAS NO: 6314-39-2
• Molecular Formula: C₁₇H₁₇NOS
• Molecular Weight: 283.388
• Mol File: 6314-39-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 477.4°C at 760 mmHg
• Flash Point: 242.5°C
• Density: 1.239g/cm³
• Vapor Pressure: 6.4E-10mmHg at 25°C
• Refractive Index: 1.692
• CAS DataBase Reference: 1-benzothiophen-2-yl[4-(dimethylamino)phenyl]methanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-benzothiophen-2-yl[4-(dimethylamino)phenyl]methanol(6314-39-2)
• EPA Substance Registry System: 1-benzothiophen-2-yl[4-(dimethylamino)phenyl]methanol(6314-39-2)

Safety Data

• Hazardous Substances Data: 6314-39-2(Hazardous Substances Data)

Usage

Molecular structure

1-benzothiophen-2-yl[4-(dimethylamino)phenyl]methanol is a chemical compound consisting of a benzothiophene ring and a dimethylamino phenyl group connected by a methanol group.

Pharmacological activities

The compound has potential medicinal properties, with the benzothiophene derivatives showing antiviral, anticancer, and anti-inflammatory activities, while the dimethylamino phenyl compounds have potential as antidepressants and antipsychotics.

Potential therapeutic applications

Due to the combination of pharmacological activities of its constituent groups, 1-benzothiophen-2-yl[4-(dimethylamino)phenyl]methanol holds promise for further research and development as a potential therapeutic agent for a range of medical conditions, including viral infections, cancer, inflammation, depression, and psychosis.

Upstream product

• 100-10-7 4-dimethylamino-benzaldehyde 
• 95-15-8 Benzo[b]thiophene 
• 50779-55-0 benzothiophen-2-yllithium 

Downstream Products

• 17347-19-2 2-(4-dimethylaminobenzyl)-benzo[b]thiophene 

Relevant articles and documents

Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin

Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

THIENYL-, FURYL- AND PYRROLYL- SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN

-